ORENCIA 250 mg, powder for concentrate for infusion bottle

Telegram WhatsApp

Link to share

Active ingredients: Abatacept

Commercialized according to BDPMDispensing in France: Prescription only, hospital use

Powder for concentrate for infusionbottleintraveineuse

No current ANSM shortage notice is included

Package details

Original BDPM fields are shown in French.

Official name: ORENCIA 250 mg, poudre pour solution à diluer pour perfusion
Pharmaceutical form: poudre pour solution à diluer pour perfusion
Route of administration: intraveineuse
Presentation description: 1 flacon(s) en verre avec 1 seringue(s) polyéthylène
Marketing authorisation holder: BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
Reimbursement according to BDPM: —
Approval for use in healthcare institutions: oui
Commercialization declaration date: 5 Dec 2011
Prescription and dispensing conditions: Prescription only, hospital use
List I: prescription-only medicine
Initial prescription by a specialist
Renewal by a specialist only
Hospital use only
Original BDPM wording: liste I · prescription initiale réservée à certains spécialistes · renouvellement de la prescription réservé aux spécialistes en DERMATOLOGIE · renouvellement de la prescription réservé aux spécialistes en MEDECINE INTERNE · renouvellement de la prescription réservé aux spécialistes en PEDIATRIE · renouvellement de la prescription réservé aux spécialistes en RHUMATOLOGIE · réservé à l'usage HOSPITALIER
Enhanced ANSM monitoring: No

BDPM identifiers

CIS60627865CIP75809893CIP133400958098932

Composition in BDPM

Composition in BDPM
Component	Amount per unit	Source type
ABATACEPTpoudre	250 mg · un flacon	SA

Information is based on BDPM data and is for reference only. Consult a doctor before use.

Similar medicines

Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.

The current BDPM data does not list similar medicines for this product.